Fertility Access After Cancer Treatment Exposes Gaps in NHS Funding
A blood cancer survivor is pressing the NHS to change fertility funding rules after being told she no longer qualified for treatment once chemotherapy was over. Her case has turned a deeply personal recovery into a wider argument about how quickly cancer care can erase the chance to have children later in life.
Mollie Mulheron, 28, was diagnosed with stage four blood cancer after doctors found a melon-sized tumour that she said was crushing her heart and left lung. She underwent about 800 hours of chemotherapy and later described the experience as hell, even as she survived the disease itself. The treatment urgency left no room to freeze her eggs before chemotherapy began.
That single timing problem has become the centre of the dispute. NICE guidance advises offering oocyte or embryo cryopreservation to women preparing for medical treatment or living with a medical condition likely to cause infertility, but the practical route to that care can depend on where a patient lives and which local NHS body is paying the bill.
Chemotherapy, Ovarian Reserve, and the Race Against Time
For young women, cancer treatment can leave fertility at risk through direct gonadotoxic effects on the ovaries, suppression of hormone production, and damage to the limited pool of remaining eggs. Chemotherapy is the most obvious threat here, but radiotherapy, surgery, hormonal therapy, and targeted therapy can also alter future reproductive potential in different ways. In Mulheron’s case, urgency mattered from the outset because aggressive cancer left no window for a standard fertility preservation cycle before treatment began.
She was later told at St James’s Hospital in Leeds that fertility preservation could still be pursued after chemotherapy. After moving to Padiham, however, she says funding was no longer available through NHS Lancashire and South Cumbria Integrated Care Board. The contrast has left her describing the system as a postcode lottery, a phrase that captures how access to reproductive care can hinge on geography rather than clinical need.
A single eligibility decision can shape the rest of a survivor’s adult life.
Mulheron said her ovarian reserve, the total remaining supply of egg cells, has fallen by more than half in a year and that she has been told early menopause is likely. For a 28-year-old, that changes more than future fertility. It can affect symptoms, long-term hormone health, and the emotional pressure of deciding whether to rush into parenthood before a survivor has had time to rebuild a life after cancer.
NICE Guidance Versus Local Commissioning Rules
The tension in this case is not about whether fertility matters after cancer. It is about how national guidance translates into funded care when local commissioning policies apply additional limits. NICE guidance supports cryopreservation for patients facing infertility due to medical treatment or disease, but Mulheron believes that advice is not enforced uniformly across NHS bodies. She argues that different interpretations have created inconsistent access to treatment for young survivors across England.
Her concern goes beyond one referral or one hospital. If preservation is offered only before treatment starts, patients with fast-moving cancers or urgent treatment plans may be excluded through no fault of their own. If funding disappears after chemotherapy, a young survivor can survive cancer only to lose the possibility of biological parenthood at the exact moment recovery finally begins. The gap between urgent oncology and reproductive planning is where many patients fall through.
The issue also carries a psychological burden. Mulheron said she does not want to feel pressured into starting a family immediately after recovery and wants time to rebuild her life. That delay matters clinically and personally. Fertility preservation is not only about the future possibility of pregnancy; it is also about preserving choice after treatment has already taken so much away.
Local Policy, Confidentiality, and the Bigger Commissioning Debate
NHS Lancashire and South Cumbria Integrated Care Board said it was aware of Mulheron’s case and understood her concerns, while explaining that decisions were in line with the current eligibility criteria of its Assisted Conception policy. The board also said it is working with Greater Manchester and Cheshire and Merseyside ICBs to review commissioning policies and that assisted conception services have been identified as a priority, particularly in light of updated national guidance.
That acknowledgement matters because fertility care sits at the intersection of oncology, reproductive medicine, and public commissioning. A clinician may recognise the need, but funding rules determine whether care happens. When access depends on local criteria, patients can receive very different answers for the same clinical problem, even when national advice points in one direction.
For cancer survivors, the consequences are concrete. Delayed access can mean declining ovarian reserve, fewer viable eggs, and a narrower path to future pregnancy. In a setting where chemotherapy has already caused irreversible reproductive harm, every administrative delay carries biological weight.
Mulheron has launched a petition calling for stronger protection of young cancer survivors’ fertility and has taken the campaign to Parliament. Her experience has made the policy issue visible, but the underlying clinical question is straightforward: if a treatment is recommended because cancer therapy may make a woman infertile, should funding disappear once that infertility risk has already been created? The answer will determine whether fertility preservation remains a matter of postcode, timing, and local interpretation or becomes a consistently available part of survivorship care.